Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 701–800 of 3,704
Faconti, L., George, J., Partridge, S., Maniero, C., Sathyanarayanan, A., Kulkarni, S., Kapil, V., Petrosino, A., Lewis, P., McCormack, T., et al. (2024) · Journal of Human Hypertension · doi:10.1038/s41371-024-00983-6 · Cited by 26
“Weight reduction obtained by the combination of a GLP-1 agonist and glucose-dependent insulinotropic polypeptide (GIP) agonists has been compared to that produced by bariatric surgery [56].”
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
Janić, M., Škrgat, S., Harlander, M., Lunder, M., Janež, A., Stoian, A. P., El‐Tanani, M., Maggio, V., & Rizzo, M. (2024) · Medicina · doi:10.3390/medicina60122030 · Cited by 34
“The adverse events that led to discontinuation of therapy were 4.3%, 7.1%, and 6.2% for 5, 10, and 15 mg of tirzepatide, respectively, and 2.6% in the placebo-treated group [30].”
InfluentialMather, K. J., Mari, A., Weerakkody, G. J., Heise, T., DeVries, J. H., Urva, S., Coşkun, T., Miličević, Z., Haupt, A., & Thomas, M. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16159 · Cited by 24
Liang, J., Liu, H., Lv, G., Chen, X., Yang, Z., Hu, K., & Sun, H. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02416-2 · Cited by 30
Stoll, F., Kantowski, T., Laaser, J., Kloiber, U., Plitzko, G., Mann, O., Aberle, J., & Lautenbach, A. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.02.004 · Cited by 20
Henney, A. E., Riley, D. R. J., Anson, M., Heague, M., Hernandez, G., Alam, U., Craig, S., & Cuthbertson, D. J. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202409-923oc · Cited by 26
Tchang, B. G., Ciudin, A., Stefański, A., García‐Pérez, L., Mojdami, D., Jouravskaya, I., Gurbuz, S., Taylor, R., Karanikas, C. A., & Dunn, J. P. (2025) · Obesity · doi:10.1002/oby.24254 · Cited by 29
“In SURMOUNT-1, more participants in the postmenopausal subgroup also had prediabetes, as defined in the main study [7].”
InfluentialSelf-citationGasoyan, H., Alavi, M. H., Zajichek, A., Casacchia, N. J., Jabri, A. A., Bena, J., Feng, X., Wilson, R. L., Corcelles, R., Butsch, W. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03893-3 · Cited by 28
“Newer GLP-1 RA medications (for example, semaglutide and tirzepatide), which can provide more favorable weight loss and cardiometabolic outcomes 12,17,25 , have become available to patients more recently and toward the end of the follow-up time (Fig.”
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
Briere, D. A., Qu, H., Lansu, K., He, M. M., Moyers, J. S., Coşkun, T., Long, A., Allen, D., O’Farrell, L. S., Bowen, B., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102271 · Cited by 26
“Gastrointestinal adverse events have also been reported with the use of GIP/GLP-1 receptor agonists, with nausea occurring in in 25 — 33% depending on the dose [32].”
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“In patients with obesity without diabetes, tirzepatide led to greater weight loss than semaglutide 366,384 , improved exercise capacity and quality of life in patients with HFpEF compared with placebo 385 , and lowered the risk of a composite of death from cardiovascular causes or worsening HF in…”
Alexander, G. C., Xiao, X., Dilek, S., Lewis, S. V., Deng, Q., Kim, M., Bolanle, D., Saldanha, I. J., & Mehta, H. B. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.8222 · Cited by 30
Romanos, M., Cordova, J. M. G., Villamarin, J. L., Zurita, J. D. P., & Acosta, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70659 · Cited by 35
Chierici, A. P., Alromayan, M., Fatico, S. D., Drai, C., Vinci, D., Anty, R., Schiavo, L., & Iannelli, A. (2023) · Journal of Liver Transplantation · doi:10.1016/j.liver.2023.100139 · Cited by 23
Current and emerging medications for the management of obesity in adults
Walmsley, R., & Sumithran, P. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51871 · Cited by 25
Engineering bacteria to modulate host metabolism
Ciocan, D. M., & Elinav, E. (2023) · Acta Physiologica · doi:10.1111/apha.14001 · Cited by 22
Camilleri, M. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14660 · Cited by 25
“62,63 Based on the acetaminophen absorption test, tirzepatide slowed gastric emptying with no evidence of tachyphylaxis over 3 weeks.”
BackgroundPharmacotherapy for obstructive sleep apnea: targeting specific pathophysiological traits
Perger, E., Bertoli, S., & Lombardi, C. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2241353 · Cited by 24
“Tirzepatide is a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist able to reduce body weight [66].”
Landgraaf, R. G., Bloem, M. N., Fumagalli, M., Benninga, M. A., de Lorijn, F., & Nieuwdorp, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1236370 · Cited by 31
Anti-obesity pharmacotherapy in adults with chronic kidney disease
Taber-Hight, E., Gilmore, A. C., & Friedman, A. N. (2023) · Kidney International · doi:10.1016/j.kint.2023.10.014 · Cited by 22
Jiménez-Franco, A., Castañé, H., Martínez-Navidad, C., Placed-Gallego, C., Hernández‐Aguilera, A., Fernández‐Arroyo, S., Samarra, I., Canela-Capdevila, M., Arenas, M., Zorzano, A., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.12.002 · Cited by 21
Locke, B. W., Gómez-Lumbreras, A., Tan, C. J., Nonthasawadsri, T., Veettil, S. K., Patikorn, C., & Chaiyakunapruk, N. (2024) · Obesity Reviews · doi:10.1111/obr.13697 · Cited by 20
“…as monotherapy only in mild cases, or select cases of moderate OSA when interventions resulting in >10% weight loss are used (for example, the predicted mean AHI improvement from tirzepatide is 13.3 events per hour [ (cid:1) 8.9 to (cid:1) 17.7] based on the SURMOUNT-1 trial 55 ; see Table S7).”
MethodInfluentialFadahunsi, N., Petersen, J., Metz, S., Jakobsen, A., Mathiesen, C. V., Buch-Rasmussen, A. S., Kurgan, N., Larsen, J. K., Andersen, R. C., Topilko, T., et al. (2024) · Science Advances · doi:10.1126/sciadv.adg2636 · Cited by 20
“An intraperitoneal glucose tolerance test was performed on day 9 of studies 1 and 6.”
Clontz, A. D., Gan, E., Hursting, S. D., & Bae-Jump, V. L. (2024) · Cancers · doi:10.3390/cancers16122197 · Cited by 25
“While bariatric surgery induces rapid excess weight loss and metabolic improvements, weight loss drugs offer a less invasive alternative, particularly suitable for individuals with lower BMI or those unwilling or ineligible for surgery [28,29].”
BackgroundLipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
Shang, R., & Rodrigues, B. B. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13199 · Cited by 21
Reis‐Barbosa, P. H., Marcondes‐de‐Castro, I. A., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15820 · Cited by 23
“16 However, although these conditions are frequently combined in menopausal women, this has not yet been investigated.”
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
“[56,57] Thus, sustained weight loss is crucial for reducing liver-related morbidity and mortality in SLD.”
BackgroundWhy are we still in need for novel anti-obesity medications?
Novikoff, A., Grandl, G., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101098 · Cited by 22
St‐Pierre, J., Klein, J. A., Choi, N. K., Fear, E., Pannain, S., & Rubin, D. T. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08720-2 · Cited by 31
“This is different from the reported changes in the literature, where a systematic review showed a decrease in total cholesterol, and both SURMOUNT-1 and STEP 1 randomized clinical trials showed a significant decrease in total cholesterol, LDL and triglyceride levels [15, 16, 19].”
InfluentialZhang, X., Xu, H., Yin, S., Gozal, D., & Khalyfa, A. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102092 · Cited by 27
Experimental and Clinical Endocrinology & Diabetes
Hu, T. F. S. H. Y. C. Z. C. J. C. W. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-00000017 · Cited by 20
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes
Heerspink, H. J. L., Friedman, A. N., Bjornstad, P., van Raalte, D. H., Cherney, D., Cao, D., Garcia-Pérez, L.-E., Stefanski, A., Turfanda, I., Bunck, M. C., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000764 · Cited by 20
“The full study designs and primary results have been previously reported, 16 ,17 and the trial designs are summarized in Supplemental Table 1.”
Self-citationSattar, N., Deanfield, J., & Delles, C. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac186 · Cited by 20
Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2025) · Pharmaceuticals · doi:10.3390/ph18050668 · Cited by 19
Aamir, A. B., Latif, R., Alqoofi, J. F., Almarzoq, F. A., Fallatah, J. O., Hassan, G. A., & Saab, F. A. A. A. A. (2025) · Journal of Clinical Medicine Research · doi:10.14740/jocmr6231 · Cited by 19
Akhtar, A., Shakir, M., Ansari, M. S., Divya, Faizan, M. I., Chauhan, V., Singh, A., Alam, R., Azmi, I., Sharma, S., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102021 · Cited by 21
Medical Nutrition Therapy: Still Relevant in the Era of Pharmacotherapy for Obesity Care
Miller, C. K. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.06.222 · Cited by 19
Obesity and Exercise: New Insights and Perspectives
James, N. M., & Stanford, K. I. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf017 · Cited by 20
Targets for obstructive sleep apnea pharmacotherapy: principles, approaches, and emerging strategies
Horner, R. L. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2240018 · Cited by 17
“In this context, tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist administered subcutaneously once a week for 72-weeks led to large and sustained reductions in body weight in obese subjects [52] (SURMOUNT-1, clinicaltrials.”
BackgroundGlucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know
Chan, P. Y. W., Mika, A. P., Martin, J. R., & Wilson, J. M. (2024) · JBJS Reviews · doi:10.2106/jbjs.rvw.23.00167 · Cited by 21
Papamargaritis, D., Al‐Najim, W., Lim, J. Z. M., Crane, J., Bodicoat, D. H., Barber, S. R., Lean, M. E. J., McGowan, B. M., O'Shea, D. B., Webb, D. R., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100853 · Cited by 22
“28,29 However, the cost of the new obesity pharmacotherapies is likely to preclude wide access and/or their long-term use.”
Gudzune, K. A., Kaplan, L. M., Kahan, S. I., Kumar, R. B., Dunn, J. P., Ahmad, N. N., Poon, J. L., Sims, T. J., Mackie, D. S., Jauregui, A. K., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.06.009 · Cited by 22
Self-citationThe role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 22
“87 Of note, the SURMOUNT studies also reported improvements in patient-reported outcomes, with participants reporting improvements in physical functioning with tirzepatide versus placebo, 83 – 86 as well as improvements in emotional and mental health scores.”
Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys
Martin, J. A., Czeskis, B. A., Urva, S., & Cassidy, K. C. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106895 · Cited by 27
Spurzem, G. J., Broderick, R. C., Ruiz-Cota, P., Hollandsworth, H. M., Sandler, B. J., Horgan, S., Grunvald, E. L., & Jacobsen, G. R. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-11308-6 · Cited by 20
Estimating the lives that could be saved by expanded access to weight-loss drugs
Pandey, A., Yang, Y., Wells, C. R., Singer, B. H., & Galvani, A. P. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2412872121 · Cited by 22
Valdecantos, M. P., Ruiz, L., Folgueira, C., Rada, P., Gómez‐Santos, B., Solas, M., Hitos, A. B., Field, J., Francisco, V., Escalona-Garrido, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54080-w · Cited by 24
“On the other hand, the dual GLP-1-glucose-dependent insulinotropic peptide (GIP) receptor agonist LY3298176 (Tirzepatide) provided substantial and sustained reductions in body weight in a 72-week trial in individuals with obesity 19 .”
Armstrong, M. J., Okanoue, T., Palle, M. S., Sejling, A., Tawfik, M., & Roden, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16065 · Cited by 21
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?
Strong, J., & Driscoll, M. S. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00911-x · Cited by 22
“Tirzepatide was also associated with significantly improved blood pressure, fasting insulin, and lipid levels compared with placebo [38].”
Wu, J., Chan, S., Hsu, W., Kuo, C., Tsai, Y., Liu, T., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16353 · Cited by 22
“12 The SURMOUNT-3 trial showed that adults with overweight or obesity achieved an additional 18.4% weight loss when continuing tirzepatide treatment after a 12-week lifestyle intervention.”
InfluentialFinan, B., Douros, J. D., Goldwater, R., Hansen, A. M. K., Hjerpsted, J., Hjøllund, K. R., Kankam, M. K., Knerr, P. J., Konkar, A. A., Mowery, S. A., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102129 · Cited by 21
“In individuals with obesity without T2D, mean body weight reduction of up to 22.5% from baseline was achieved with tirzepatide [8].”
InfluentialCVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 24
“In addition, CV benefits, including reduction in the number of HHF, have been observed with SGLT2is [23–27, In metabolic outcome trials, significant effects on weight reduction were shown with semaglutide (GLP-1RA) [48–51] and tirzepatide (dual GIP/GLP-1 RA)[52– 57] in people with or without T2D.”
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“In clinical trials, tirzepatide and semaglutide reduced body weight by up to 23.6% and 17.4%, respectively [58,194].”
InfluentialBharaj, I. S., Brar, A. S., Kahlon, J., Singh, A., Hotwani, P., Kumar, V., Sohal, A., & Batta, A. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i6.106147 · Cited by 19
Sinha, B., & Ghosal, S. (2025) · Obesity · doi:10.1002/oby.24360 · Cited by 31
“Nineteen RCTs ( N = 29,506) evaluated liraglutide [4, 8–11], oral and injectable semaglutide [3, 12, 13, 17–21], orforglipron [12], tirzepatide [22–24], retatrutide [15, 16], survodutide [14], and placebo over 36–104 weeks (Table 1).”
Auerbach, N., Liu, V. N., Huang, D. R., Clift, A. K., Al-Ammouri, M., & El-Osta, A. A. R. (2025) · BMJ Public Health · doi:10.1136/bmjph-2024-002519 · Cited by 31
“9 The use of GLP-1 receptor agonists among individuals with overweight or obesity (but without diabetes) increased by more than 700% between 2019 and 2023, reflecting a dramatic surge in popularity.”
Sabatella, L., Ortega, P., Valentí, V., Rotellar, F., Pagola, A. U., Ahmed, A., Purkayastha, S., Tuero, C., Blanco, N., & Landecho, M. F. (2025) · Obesity · doi:10.1002/oby.70100 · Cited by 32
“However, it is important to note that the maximum follow-up duration for pharmacological interventions included in our analysis was 176 weeks, which inherently limits our capacity to comprehensively assess and compare the true long-term durability of GLP-1 RA therapy relative to MBS [21].”
Toki, S., Zhang, J., Printz, R. L., Newcomb, D. C., Cahill, K. N., Niswender, K. D., & Peebles, R. S. (2022) · Clinical & Experimental Allergy · doi:10.1111/cea.14252 · Cited by 23
Mirghani, H. O., & Albalawi, I. A. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01001-4 · Cited by 24
“Anti-diabetes medications in particular sodium-glucose co-transporters-2 inhibitors and glucagon-like peptide agonists were shown to induce diabetes remission in particular when combined with other therapies including insulin [49, 50].”
BackgroundFanshier, A. V., Crews, B. K., Garrett, M. C., & Johnson, J. L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0060 · Cited by 22
van Eenige, R., Ying, Z., Tramper, N., Wiebing, V., Siraj, Z., de Boer, J. F., Lambooij, J. M., Guigas, B., Qu, H., Coşkun, T., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.016 · Cited by 20
Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
Genchi, V. A., Palma, G., Sorice, G. P., D’Oria, R., Caccioppoli, C., Marrano, N., Biondi, G., Caruso, I., Cignarelli, A., Natalicchio, A., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02125-0 · Cited by 23
“Noteworthy, the degree of body weight reduction with matzutide was similar to what was observed with tirzepatide (approximately 10% of body weight) after 12 weeks of treatment in patients with T2D and obesity, even though these data are referred to different study populations [195, 223].”
ResultGPCR-mediated effects of fatty acids and bile acids on glucose homeostasis
Oteng, A., & Liu, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1206063 · Cited by 25
“In the context of obesity and diabetes, a recently approved drug, tirzepatide, is highly efficacious in reducing body weight and decreasing HbA1c levels (23, 24).”
BackgroundBreaking down silos: the multifaceted nature of obesity and the future of weight management
Heeren, F. A. N., Darcey, V. L., Deemer, S. E., Menon, S., Tobias, D. K., & Cardel, M. I. (2023) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0215 · Cited by 23
Treating obesity in type 1 diabetes mellitus – review of efficacy and safety
Freeby, M., & Lane, K. L. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000841 · Cited by 23
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Kumar, A., Mazumder, R., Rani, A., Pandey, P., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998261903230921102620 · Cited by 24
Game changers: do new medications make lifestyle‐based treatment of obesity obsolete?
Lewis, K. H., Moore, J. B., & Ard, J. D. (2023) · Obesity · doi:10.1002/oby.23962 · Cited by 20
“…medications (AOMs) coming to market that boast impressive safety and weight-loss profiles, many patients and providers are starting to view medication as an attractive option to support long-term weight management, possibly without the need for much accompanying lifestyle intervention [7].”
BackgroundMethodSchmidt, P. H. S., Pasqualotto, E., dos Santos, H. V., de Souza, L. S. N., dos Santos, B. E., Chavez, M. P., Ferreira, R. O. M., Hohl, A., Ronsoni, M. F., & van de Sande-Lee, S. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.009 · Cited by 18
Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus
Kelly, M. S., Scopelliti, E. M., Goodson, K. E., Lo, C. M. A., Nguyen, H. X., & Simon, B. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15934 · Cited by 21
Bays, H. E., Burridge, K., Richards, J., & Fitch, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100039 · Cited by 18
Obesity Modifies Clinical Outcomes of Right Ventricular Dysfunction
Ma, J. I., Zern, E. K., Parekh, J. K., Owunna, N., Jiang, N. M., Wang, D., Rambarat, P. K., Pomerantsev, E. V., Picard, M. H., & Ho, J. E. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010524 · Cited by 23
Nutritional Mechanisms of Cancer Cachexia
Compton, S. L. E., Heymsfield, S. B., & Brown, J. C. (2024) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062122-015646 · Cited by 26
Effects of Tirzepatide in Type 2 Diabetes
Aminorroaya, A., Oikonomou, E. K., Biswas, D., Jastreboff, A. M., & Khera, R. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.516 · Cited by 22
Self-citationSafwan, M., Bourgleh, M. S., Alotaibi, S. A., Alotaibi, E. A., Al-Ruqi, A., & Raeya, F. E. (2025) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2025.129 · Cited by 78
“Two of the included studies (O’Neil et al and Jastreboff et al) 16,26 had multiple intervention groups that were combined into a single group to facilitate inclusion in the pooled analysis.”
Rodríguez, R., Hergarden, A. C., Krishnan, S., Morales, M., Lam, D., Tracy, T., Tang, T., Patton, A., Lee, C. R., Pant, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102156 · Cited by 34
Ciudin, A., Johansson, E., Zimner‐Rapuch, S., Dimitriadis, G. K., Bertrand, M., Curteis, T., Clark, L. J., Fan, L., Sapin, H., & Bergmann, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16508 · Cited by 28
“22 23 – 26 SURMOUNT-2 is the pivotal trial of tirzepatide for obesity and overweight management in participants with T2D.”
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence
Sattar, N. A., García‐Pérez, L., Rodríguez, Á., Kapoor, R., Stefański, A., & Hankosky, E. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16549 · Cited by 28
“13 Similar improvements in SBP, DBP, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides were reported for participants receiving tirzepatide compared with placebo in the phase 3 clinical trials SURMOUNT-3 14 and SURMOUNT-4, 15 and consistent…”
Self-citationSouto, M., Gonçalves, T. C., & Cotter, J. B. (2025) · Nutrients · doi:10.3390/nu17142310 · Cited by 26
“In clinical trials, such as SURMOUNT-1 and SURPASS, it demonstrated superior weight loss compared to other existing therapies [129–132].”
Caussy, C., Cusi, K. J., Rosenstock, J., Bugianesi, E., Thomas, M. K., Tang, Y., Mather, K. J., Loomba, R., Sanyal, A. J., & Hartman, M. L. (2025) · Diabetes Care · doi:10.2337/dc25-1306 · Cited by 33
Survodutide Once Weekly for the Treatment of Adults with Obesity
le Roux, C. W., Wharton, S., Startseva, E., Kloer, I. M., Hussain, S. A., Unseld, A., Bozkurt, B., Ard, J. D., Bays, H. E., Bogdański, P., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600751 · Cited by 35
Self-citationNew Horizons: Emerging Antidiabetic Medications
Mingrone, G., Castagneto‐Gissey, L., & Bornstein, S. R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac499 · Cited by 22
Cuda, S. E., Censani, M., Kharofa, R. Y., O’Hara, V. M., Conroy, R., Williams, D. R., Paisley, J., Browne, A. F., Karjoo, S., & Browne, N. T. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100048 · Cited by 22
“Tirzepatide was evaluated for management of obesity in the 2022 SURMOUNT-1 trial, but is not yet FDA approved for obesity in adults or children [100].”
BackgroundInfluentialObesity and diabetes: the final frontier
Rendell, M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2168643 · Cited by 23
Research Priorities for Precision Medicine in NAFLD
Iruzubieta, P., Bataller, R. A., Arias, M., Arrese, M. A., Calleja, J. L., Castro‐Narro, G., Cusi, K. J., Dillon, J. F., Martínez‐Chantar, M. L., Mateo, M., et al. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.016 · Cited by 20
Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
Oduah, M.-T. A., Sundaram, V., & Reddy, Y. N. V. (2023) · Cardiac failure review · doi:10.15420/cfr.2022.25 · Cited by 20
A review of the evidence on cardiovascular outcomes from obesity treatment
Wahab, R. A., & le Roux, C. W. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100071 · Cited by 21
“Tirzepatide is a once weekly subcutaneous injectable peptide derived from the glucose-dependent insulinotropic polypeptide (GIP) sequence, with dual agonist activity at GIP and GLP-1 receptor [55], which provided substantial and sustained reductions in body weight [10].”
BackgroundStefanakis, K., Kokkinos, A. D., Argyrakopoulou, G., Konstantinidou, S. M., Simati, S., Kouvari, M., Kumar, A., Kalra, B., Kumar, M., Bontozoglou, N., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15141 · Cited by 20
Rohani, P., Malekpour Alamdari, N., Bagheri, S. E., Hekmatdoost, A., & Sohouli, M. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1230206 · Cited by 18
“2022 (32) Multicenter (Countries not reported) 3 Obesity 45 32.”
ResultRecent updates on pharmacologic therapy in non-alcoholic fatty liver disease
Chang, Y. W., Jeong, S. W., & Jang, J. Y. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0356 · Cited by 22
“Recently, pegbelfermin has failed to demonstrate significant reductions in liver fibrosis in patients with NASH.”
InfluentialGupta, U., Ruli, T. M., Buttar, D., Shoreibah, M., & Gray, M. E. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.11.007 · Cited by 21
Weight Loss Treatment and Longitudinal Weight Change Among Primary Care Patients With Obesity
Henderson, J., Ehlers, A. P., Lee, J. M., Kraftson, A. T., Piehl, K., Richardson, C. R., & Hafez, D. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.56183 · Cited by 21
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Horváth, L., Mráz, M., Jude, E. B., & Haluzík, M. (2024) · Drugs · doi:10.1007/s40265-024-02029-0 · Cited by 22
“In contrast to GLP-1 RAs, tirzepatide is a dual agonist of both GLP-1R and glucose-dependent insulino-tropic polypeptide-receptor (GIP-R) [125].”
BackgroundResultInfluentialPuttarajappa, C. M., Smith, K. J., Ahmed, B. H., Bernardi, K., Lavenburg, L.-M. U., Hoffman, W., & Molinari, M. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.07.024 · Cited by 20
Despain, D., & Hoffman, B. L. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100143 · Cited by 19
“They operate by enhancing insulin secretion in response to food intake without risking hypoglycemia and effectively reduce appetite and body weight [2 – 5].”
BackgroundChronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
Davies, I., Adriaenssens, A. E., Scott, W. R., Carling, D., Murphy, K. G., MINNION, J. S., Bloom, S. R., Jones, B. J., & Tan, T. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102094 · Cited by 20
Ard, J. D., Hong, Y., Foster, G. D., Medcalf, A., Nadolsky, S., & Cardel, M. I. (2024) · Obesity · doi:10.1002/oby.24169 · Cited by 18
“…revealed significant insights into who used the service, patterns of treat-ment In comparing these data with the SURMOUNT-1 (tirzepatide), STEP-1 (semaglutide 2.4 mg), and SCALE (liraglutide 3.0 mg) trials, there are notable differences and similarities in study populations and outcomes [3, 5, 9].”
InfluentialLiu, S., Hu, J., Zhao, C., Liu, H., & He, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1513641 · Cited by 17
Recent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Edwards‐Hampton, S. A., & Ard, J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15819 · Cited by 17
“The emergence of third-generation antiobesity medications (AOMs) that are incretin-based, long-acting, and tend to achieve average weight losses of 15% 83,84 or more means that MR combined with these treatments can be used with a greater sense of self-efficacy and ease of implementation.”
Griffin, J. D., Zhu, Y., Reeves, A., Buhman, K. K., & Greenberg, A. S. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101918 · Cited by 20
“The success of bariatric surgery [3] and drugs targeting enteroendocrine signaling (e.g. glucagon like peptide 1 (GLP-1) receptor agonists) [4,5] in improving adiposity and metabolic health highlights the importance of dietary fat digestion, absorption, and signaling in regulating energy…”
Background
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.